韩国的噬菌体疗法:韩国传染病专家对噬菌体疗法态度的处方调查。

IF 2.8 Q2 INFECTIOUS DISEASES Infection and Chemotherapy Pub Date : 2024-03-01 Epub Date: 2023-12-01 DOI:10.3947/ic.2023.0067
Shinwon Lee, Stephanie Lynch, Ruby C Y Lin, Heejoon Myung, Jonathan R Iredell
{"title":"韩国的噬菌体疗法:韩国传染病专家对噬菌体疗法态度的处方调查。","authors":"Shinwon Lee, Stephanie Lynch, Ruby C Y Lin, Heejoon Myung, Jonathan R Iredell","doi":"10.3947/ic.2023.0067","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Concerns about the rise in antimicrobial resistance have led to renewed interest in phage therapy worldwide, but perceptions among relevant medical professionals in Korea remain largely unknown.</p><p><strong>Materials and methods: </strong>We conducted a semi-quantitative online survey to evaluate the Korean infectious disease specialists' perception of phage therapy.</p><p><strong>Results: </strong>We sent out the link to the questionnaire to 380 subjects and received 91 replies, with 90/91 respondents identifying as Korean infectious diseases specialists or trainees. Ten out of 91 (11.0%) respondents scored themselves as well-informed about phage therapy. The majority (93.4%) of respondents would consider using phage therapy if the safety of the phage formulation is guaranteed, and 80% of respondents would consider participating in clinical trials with phage therapy given adequate support. The biggest concern was uncertainty about safety (73.6%) and efficacy (65.9%). <i>Acinetobacter baumannii</i> was ranked as a high priority for phage therapy research, as were bone and joint infections.</p><p><strong>Conclusion: </strong>Korean infectious diseases specialists are receptive to phage therapy, but a better understanding of safety, efficacy and clinical trials are warranted to progress phage therapy within the Korean healthcare system.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":" ","pages":"57-65"},"PeriodicalIF":2.8000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990887/pdf/","citationCount":"0","resultStr":"{\"title\":\"Phage Therapy in Korea: A Prescribers' Survey of Attitudes Amongst Korean Infectious Diseases Specialists Towards Phage Therapy.\",\"authors\":\"Shinwon Lee, Stephanie Lynch, Ruby C Y Lin, Heejoon Myung, Jonathan R Iredell\",\"doi\":\"10.3947/ic.2023.0067\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Concerns about the rise in antimicrobial resistance have led to renewed interest in phage therapy worldwide, but perceptions among relevant medical professionals in Korea remain largely unknown.</p><p><strong>Materials and methods: </strong>We conducted a semi-quantitative online survey to evaluate the Korean infectious disease specialists' perception of phage therapy.</p><p><strong>Results: </strong>We sent out the link to the questionnaire to 380 subjects and received 91 replies, with 90/91 respondents identifying as Korean infectious diseases specialists or trainees. Ten out of 91 (11.0%) respondents scored themselves as well-informed about phage therapy. The majority (93.4%) of respondents would consider using phage therapy if the safety of the phage formulation is guaranteed, and 80% of respondents would consider participating in clinical trials with phage therapy given adequate support. The biggest concern was uncertainty about safety (73.6%) and efficacy (65.9%). <i>Acinetobacter baumannii</i> was ranked as a high priority for phage therapy research, as were bone and joint infections.</p><p><strong>Conclusion: </strong>Korean infectious diseases specialists are receptive to phage therapy, but a better understanding of safety, efficacy and clinical trials are warranted to progress phage therapy within the Korean healthcare system.</p>\",\"PeriodicalId\":51616,\"journal\":{\"name\":\"Infection and Chemotherapy\",\"volume\":\" \",\"pages\":\"57-65\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990887/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infection and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3947/ic.2023.0067\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/12/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infection and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3947/ic.2023.0067","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:对抗菌药耐药性上升的担忧使全世界对噬菌体疗法重新产生了兴趣,但韩国相关医疗专业人员对噬菌体疗法的看法在很大程度上仍不为人所知:我们进行了一项半定量在线调查,以评估韩国传染病专家对噬菌体疗法的看法:我们向 380 名受访者发送了问卷链接,收到 91 份回复,其中 90/91 名受访者自称是韩国传染病专家或受训人员。91 位受访者中有 10 位(11.0%)认为自己对噬菌体疗法非常了解。如果噬菌体制剂的安全性有保证,大多数受访者(93.4%)会考虑使用噬菌体疗法,如果有足够的支持,80% 的受访者会考虑参加噬菌体疗法的临床试验。最大的担忧是安全性(73.6%)和疗效(65.9%)的不确定性。鲍曼不动杆菌和骨关节感染被列为噬菌体疗法研究的重点:结论:韩国传染病专家乐于接受噬菌体疗法,但要在韩国医疗保健系统中推广噬菌体疗法,还需要更好地了解其安全性、有效性和临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Phage Therapy in Korea: A Prescribers' Survey of Attitudes Amongst Korean Infectious Diseases Specialists Towards Phage Therapy.

Background: Concerns about the rise in antimicrobial resistance have led to renewed interest in phage therapy worldwide, but perceptions among relevant medical professionals in Korea remain largely unknown.

Materials and methods: We conducted a semi-quantitative online survey to evaluate the Korean infectious disease specialists' perception of phage therapy.

Results: We sent out the link to the questionnaire to 380 subjects and received 91 replies, with 90/91 respondents identifying as Korean infectious diseases specialists or trainees. Ten out of 91 (11.0%) respondents scored themselves as well-informed about phage therapy. The majority (93.4%) of respondents would consider using phage therapy if the safety of the phage formulation is guaranteed, and 80% of respondents would consider participating in clinical trials with phage therapy given adequate support. The biggest concern was uncertainty about safety (73.6%) and efficacy (65.9%). Acinetobacter baumannii was ranked as a high priority for phage therapy research, as were bone and joint infections.

Conclusion: Korean infectious diseases specialists are receptive to phage therapy, but a better understanding of safety, efficacy and clinical trials are warranted to progress phage therapy within the Korean healthcare system.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Infection and Chemotherapy
Infection and Chemotherapy INFECTIOUS DISEASES-
CiteScore
6.60
自引率
11.90%
发文量
71
审稿时长
22 weeks
期刊最新文献
Quinolone Use during the First Trimester of Pregnancy and the Risk of Atopic Dermatitis, Asthma, and Allergies of Offspring during 2011 to 2020. Use of a Real-Time Locating System in Infection Control. Clinical and Microbiological Characteristics of ST72 Methicillin-Susceptible Staphylococcus aureus: Comparison with ST72 Methicillin-Resistant S. aureus. Clinical Outcomes of Solid Organ Transplant Recipients Hospitalized with COVID-19: A Propensity Score-Matched Cohort Study. Addressing Campylobacter AMR Transmission in India: Urgent Policy Call.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1